Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma (NAPSTER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05024318
Recruitment Status : Not yet recruiting
First Posted : August 27, 2021
Last Update Posted : October 6, 2021
Sponsor:
Information provided by (Responsible Party):
Peter MacCallum Cancer Centre, Australia

Brief Summary:
This is a prospective, open label, phase II, randomised, non-comparative clinical trial, evaluating changes in tumour-responsive T-cells following neoadjuvant stereotactic ablative body radiotherapy (SABR) with or without pembrolizumab, prior to nephrectomy, in patients with localised primary clear cell renal cell carcinoma (ccRCC).

Condition or disease Intervention/treatment Phase
Renal Cell Carcinoma, Clear Cell, Somatic Drug: Pembrolizumab Radiation: Stereotactic Ablative Radiotherapy Procedure: Nephrectomy Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma: Investigating Induced Immune Context Changes
Estimated Study Start Date : November 2021
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2023


Arm Intervention/treatment
Active Comparator: SABR plus nephrectomy
Stereotactic Ablative Radiotherapy (SABR) will be prescribed to a dose of 42Gy in 3 fractions. All radiotherapy treatment be completed within 3 weeks.Patients will undergo nephrectomy within 9-12 weeks after the first dose of treatment.
Radiation: Stereotactic Ablative Radiotherapy
42Gy delivered in 3 fractions
Other Name: SABR

Procedure: Nephrectomy
Partial or total nephrectomy performed 9-12 weeks after first dose of Pembrolizumab
Other Name: Surgical removal of a kidney

Experimental: Pembrolizumab followed by SABR after cycle 1 plus nephrectomy
Pembrolizumab 200 mg (flat dose) will be administered as a 30 minute IV infusion every 21 days for 3 cycles. Patients will receive 1 cycle of pembolizumab prior to SABR followed by an additional 2 cycles of pembrolizumab (1 cycle is 21 days). Patients will undergo nephrectomy 9-12 weeks after commencement of treatment.
Drug: Pembrolizumab
Pembrolizumab 200 mg tobe administered as a 30 minute IV infusion every 21 days for 3 cycles
Other Name: MK-3475

Radiation: Stereotactic Ablative Radiotherapy
42Gy delivered in 3 fractions
Other Name: SABR

Procedure: Nephrectomy
Partial or total nephrectomy performed 9-12 weeks after first dose of Pembrolizumab
Other Name: Surgical removal of a kidney




Primary Outcome Measures :
  1. mPR post-SABR with or without pembrolizumab [ Time Frame: At nephrectomy performed 9-12 weeks after first dose of pembrolizumab ]
    The mPR rate is defined as <10% residual tumour at post-nephrectomy specimens

  2. CD8+ TRM in baseline biopsy and post-nephrectomy specimen, all measured as a continuous variable. [ Time Frame: Baseline and at nephrectomy performed 9-12 weeks after first dose of pembrolizumab ]
    To describe changes in tumour-responsive T-cells, TRM CD8+ T-cells from baseline to post-nephrectomy in patients treated with SABR with or without pembrolizumab treatment followed by nephrectomy

  3. TCF-1 + tumour infiltrating lymphocytes (TILs) in baseline biopsy and post-nephrectomy specimen, measured as a continuous variable [ Time Frame: Baseline and at nephrectomy performed 9-12 weeks after first dose of pembrolizumab ]
    To describe changes in TCF-1+ T-cells from baseline to post-nephrectomy in patients treated with SABR with or without pembrolizumab treatment followed by nephrectomy


Secondary Outcome Measures :
  1. Immune response cells in baseline biopsy and post-nephrectomy specimen [ Time Frame: Baseline and at nephrectomy performed 9-12 weeks after first dose of pembrolizumab ]
    Change in immune response from baseline to post-nephrectomy

  2. The tumour-responsive TRM cells inclusive of CD4+ and CD8+ compartments [ Time Frame: 2 weeks prior to nephrectomy ]
    Percentage of tumour responsive T-cells (inclusive CD4/CD8) after neo-adjuvant treatment

  3. Safety of SABR with or without pembrolizumab in the neo-adjuvant setting [ Time Frame: 60 days post nephrectomy ]
    Adverse events, as measured by CTCAE v5.0

  4. Change in immune response associated with mPR [ Time Frame: Baseline and at nephrectomy performed 9-12 weeks after first dose of pembrolizumab ]
    Immune response cells in baseline biopsy and post-nephrectomy specimens

  5. Change in PD-L1 and PD-L2 expression in tumour [ Time Frame: Baseline and at nephrectomy performed 9-12 weeks after first dose of pembrolizumab ]
    PD-L1 and PD-L2 expression in baseline biopsy and post-nephrectomy specimens


Other Outcome Measures:
  1. Radiological features including contrast enhancement consistent with mPR [ Time Frame: 2 weeks prior to nephrectomy ]
    Post treatment radiological features including contrast enhancement

  2. Radiological features including size reduction consistent with mPR [ Time Frame: 2 weeks prior to nephrectomy ]
    Post treatment radiological features including size reduction

  3. Radiological features including maximum tumour diameter consistent with mPR [ Time Frame: 2 weeks prior to nephrectomy ]
    Post treatment radiological features including maximum tumour diameter

  4. Radiological features including margins consistent with mPR [ Time Frame: 2 weeks prior to nephrectomy ]
    Post treatment radiological features including margins

  5. Baseline versus post-nephrectomy tissue for immune context changes [ Time Frame: Baseline and at nephrectomy performed 9-12 weeks after first dose of pembrolizumab ]
    To investigate baseline versus post-nephrectomy tissue for immune context changes, using a broad panel of assays which will be further developed through the lifetime of the study

  6. Baseline versus post-nephrectomy tissue immune network signalling [ Time Frame: Baseline and at nephrectomy performed 9-12 weeks after first dose of pembrolizumab ]
    Baseline and post-nephrectomy immune network signalling , using a broad panel of assays which will be further developed through the lifetime of the study

  7. Systemic immune cells in baseline and post-nephrectomy blood samples [ Time Frame: Baseline and at nephrectomy performed 9-12 weeks after first dose of pembrolizumab ]
    To investigate changes in systemic immunity of patients with primary ccRCC treated with SABR with or without pembrolizumab



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient has provided written informed consent
  2. Male or female aged 18 years or older at written informed consent
  3. Histologically or cytologically confirmed diagnosis of RCC with clear cell, rhabdoid or sarcomatoid components
  4. Tumour stage T1B-T3, N0 or N1, M0 or low volume M1 planned for nephrectomy
  5. Patients must have adequate bone marrow, hepatic and renal function documented within 14 days prior to randomisation:

    • White Blood Cell (WBC) ≥ 3 X 10^9/L
    • Absolute neutrophil count (ANC) ≥1.5 X 10^9/L
    • Platelets ≥ 100 X 10^9/L
    • Haemoglobin ≥ 100 g/L independent of transfusion
    • Serum Creatinine ≤1.5 X Upper Limit of Normal (ULN) or measured or calculated CrCl calculated as per institutional standard ≥ 30 ml/min. GFR can also be used in place of serum creatinine or CrCl.
    • Total bilirubin ≤1.5 X ULN except for patients with known Gilbert's Syndrome
    • Albumin > 30 g/L
    • AST and ALT ≤1.5 X ULN
    • INR or PT ≤1.5 X ULN unless patient is receiving anticoagulant therapy
  6. ECOG performance status of 0 or 1
  7. Women of child birth potential (WOCBP) must have a negative urine or serum pregnancy test within 72 hours prior to randomisation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  8. WOCBP should be willing to use two methods of birth control, or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Patients of childbearing potential are those who have not been surgically sterilised or have not been free from menses for more than 1 year
  9. Male patients should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy
  10. Patient agrees to the collection and use of their fresh tumour samples and peripheral blood for translational research
  11. Patient is willing and able to comply with the protocol for the duration of the study including undergoing biopsies, treatment, and scheduled visits and examination

Exclusion Criteria:

  1. Had prior treatment with any anti-PD-1, or anti-PD-L1, or PD-L2 agent or with an antibody targeting any other immune-regulatory receptors or mechanisms. Examples of such antibodies include antibodies against IDO, PD-L1, IL-2R, and GITR
  2. Known or active inflammatory bowel disease involving colon and small bowels
  3. Previous radiotherapy to the upper abdomen with radiation dose overlap to the involved kidney
  4. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to randomisation
  5. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy exceeding 10 mg daily dose of prednisone or equivalent or any other form of immunosuppressive therapy within 7 days prior to randomisation
  6. Has an active autoimmune disease that has required systemic treatment in the last 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed
  7. Has a known additional malignancy that is progressing or has required active treatment in the last 3 years Note: Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ, such as breast cancer in situ, that has undergone potentially curative therapy are not excluded
  8. Has known active CNS metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to randomisation
  9. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients
  10. Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
  11. Has an active infection requiring systemic therapy
  12. Has a known history of HIV infection
  13. Has known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive)or known active Hepatitis C (defined as HCV RNA [qualitative] is detected) infection
  14. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating investigator
  15. Has a known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  16. Has received a live virus vaccine within 30 days prior to randomisation. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed
  17. Has had a prior solid organ transplant
  18. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study drug.
  19. Any contraindications for surgery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05024318


Contacts
Layout table for location contacts
Contact: Shankar Siva, A/Prof +61 3 8559 7988 Shankar.Siva@petermac.org
Contact: Arun Azad, A/Prof +61 3 8559 7165 Arun.Azad@petermac.org

Locations
Layout table for location information
Australia, Victoria
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia, 3000
Contact: Shankar Siva, A/Prof    +61 3 8559 7988    Shankar.Siva@petermac.org   
Contact: Arun Azad, A/Prof    +61 3 8559 7165    Arun.Azad@petermac.org   
Sponsors and Collaborators
Peter MacCallum Cancer Centre, Australia
Investigators
Layout table for investigator information
Study Chair: Shankar Siva, A/Prof Peter MacCallum Cancer Centre, Australia
Layout table for additonal information
Responsible Party: Peter MacCallum Cancer Centre, Australia
ClinicalTrials.gov Identifier: NCT05024318    
Other Study ID Numbers: 19/007
First Posted: August 27, 2021    Key Record Dates
Last Update Posted: October 6, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents